Advertisement

Advertisement
Richard I. Fisher, MD, on Follicular Lymphoma: Optimizing First-Line Therapy

Richard I. Fisher, MD, on Follicular Lymphoma: Optimizing First-Line Therapy

Nivolumab for Children and Young Adults With Relapsed or Refractory Solid Tumors or Lymphoma

In a phase I/II study reported in The Lancet Oncology, Davis et al identified the phase II dosage of nivolumab monotherapy in children and young adults with relapsed or refractory solid tumors or lymphoma. Objective responses were observed in patients with lymphoma, but not in those with solid tumors.

Quality of Life With Tisagenlecleucel Therapy for Relapsed or Refractory DLBCL

Adult patients with diffuse large B-cell lymphoma (DLBCL) whose disease was effectively treated with the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel showed sustained and clinically meaningful improvement in a variety of self-reported quality-of-life measures, according to research findings reported by Maziarz et al in the journal Blood Advances

Bispecific Antibody Shows Activity in Post–CAR T-Cell Therapy for Non-Hodgkin Lymphoma

Mosunetuzumab, an ­investigational ­bispecific antibody, demonstrated activity in preliminary studies of patients with non-Hodgkin lymphoma (NHL), including those who are refractory to or relapsed after third-line chimeric antigen receptor (CAR) T-cell therapy.

Haploidentical Related Donor vs Unrelated Cord Blood Hematopoietic Cell Transplantation for Hodgkin and Non-Hodgkin Lymphomas

In a retrospective analysis reported in the Journal of Clinical Oncology, Fatobene et al found that nonmyeloablative haploidentical related donor cell transplantation was associated with better outcomes compared to unrelated cord blood hematopoietic transplantation in patients with Hodgkin and non-Hodgkin lymphomas.

Study Finds ‘Bridge’ to CAR T-Cell Therapy May Be Detrimental to Survival

The use of bridging therapy before treatment with axicabtagene ciloleucel was associated with worse overall survival in univariate, multivariate, and propensity score–matched analyses performed on data from the U.S. Lymphoma CAR T Consortium, investigators reported at the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition.

Advertisement


Advertisement